These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 23829615)
41. [Similar poor response in genotype 4 chronic Hepatitis C treatment with interferon and ribavirin compared with genotype 1 treatment]. Pérez Mota A; Graus J; García Flores MA; Blanco M; Pérez-Muñoz C; Villalgordo C; Rodero R Rev Esp Enferm Dig; 2003 Mar; 95(3):238-9. PubMed ID: 12760714 [No Abstract] [Full Text] [Related]
42. [International consensus conference on hepatitis C. Conclusions. Organized under the auspices of the European Association for the Study of the Liver (EASL)]. Ann Med Interne (Paris); 1999 Sep; 150(5):449-53. PubMed ID: 10544760 [No Abstract] [Full Text] [Related]
43. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question? Shedlofsky SI Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712 [No Abstract] [Full Text] [Related]
44. New therapeutic strategies for hepatitis C. Di Bisceglie AM; McHutchison J; Rice CM Hepatology; 2002 Jan; 35(1):224-31. PubMed ID: 11786980 [No Abstract] [Full Text] [Related]
46. Treatment of hepatitis C infection. Review underplayed important public health issues. Agarwal K; Jones DD BMJ; 1999 Aug; 319(7207):450-1. PubMed ID: 10445936 [No Abstract] [Full Text] [Related]
47. Hepatitis C: a challenge for the generalist. Catalina G; Navarro V Hosp Pract (1995); 2000 Jan; 35(1):97-8, 101-4, 107-8 passim. PubMed ID: 10645992 [TBL] [Abstract][Full Text] [Related]
48. Controlling hepatitis C with immunotherapy. Wen Y; feng LY; Jing Y; Xin L; Zhikai X Lancet Infect Dis; 2009 Nov; 9(11):652-3. PubMed ID: 19850221 [No Abstract] [Full Text] [Related]
49. Infectious diseases. Hard-won advances spark excitement about hepatitis C. Crabb C Science; 2001 Oct; 294(5542):506-7. PubMed ID: 11641482 [No Abstract] [Full Text] [Related]
50. Consensus among consensus conferences on management of hepatitis C: what we knew then and are still sure about, what we are newly sure about, and what we still need to know. Farrell GC J Gastroenterol Hepatol; 2000 May; 15 Suppl():E126-9. PubMed ID: 10921395 [No Abstract] [Full Text] [Related]
51. Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era. Raja R; Baral S; Dixit NM Immunol Rev; 2018 Sep; 285(1):55-71. PubMed ID: 30129199 [TBL] [Abstract][Full Text] [Related]
52. Treatment of chronic hepatitis C virus infection: a clinical and virological perspective. Gretch DR; Polyak SJ; Willson RA; Carithers RL Adv Exp Med Biol; 1996; 394():207-24. PubMed ID: 8815687 [No Abstract] [Full Text] [Related]
53. Hepatitis treatment in developing countries. Smeeth L Lancet; 1998 Nov; 352(9141):1711-2. PubMed ID: 9853475 [No Abstract] [Full Text] [Related]
54. New guidelines on hepatitis C. Tanne JH BMJ; 1997 Apr; 314(7087):1070. PubMed ID: 9133883 [No Abstract] [Full Text] [Related]
58. Interferon and chronic non-A, non-B hepatitis: whom are we treating? Koretz RL Hepatology; 1990 Sep; 12(3 Pt 1):613-5. PubMed ID: 1698172 [No Abstract] [Full Text] [Related]
59. Ribavirin for hepatitis C infection. James DG Postgrad Med J; 1995 Feb; 71(832):120. PubMed ID: 7536917 [No Abstract] [Full Text] [Related]
60. Hepatitis C in Australia - a role for general practitioners? van Driel ML; Lim D; Clark PJ Med J Aust; 2017 Jul; 207(2):53. PubMed ID: 28701119 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]